Hansa Biopharma AB - Company Profile

Powered by

All the sales intelligence you need on Hansa Biopharma AB in one solution.

$ $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Hansa Biopharma AB fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Hansa Biopharma AB.

Back to companies

Hansa Biopharma AB: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Hansa Biopharma AB (Hansa Biopharma) is a commercial-stage biopharmaceutical company which develops and commercializes treatments for patients with rare immunological conditions. The company's antibody-cleaving enzyme technology platform targets pathogenic or disease-causing antibodies. Its major product, Imlifidase, is designed to rapidly and specifically inactivate IgG antibodies in plasma and tissue. Hansa Biopharma's products primarily find applications across transplantation, autoimmune diseases, gene therapy, and oncology. The company collaborates with strategic partners such as Sarepta Therapeutics and AskBio to maximize the potential of its technology platform. The company operates in various European countries and the US, targeting markets with significant unmet medical needs. Hansa Biopharma is headquartered in Lund, Sweden.

 Gain a 360-degree view of Hansa Biopharma AB and make more informed decisions for your business Gain a 360-degree view of Hansa Biopharma AB and make more informed decisions for your business Learn more
Headquarters Sweden
Address Box 785, Lund, 22007
Website www.hansabiopharma.com
Telephone 46 46 165670
No of Employees 122
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange HNSA (STO)
Revenue (2024) $22.7M 29.7% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 33.8% (2024 vs 2023)
Market Cap* $364.0M
Net Profit Margin (2024) XYZ 49.0% (2024 vs 2023)
* As of and is in US$
View Hansa Biopharma AB financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Hansa Biopharma AB premium industry data and analytics

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Hansa Biopharma AB’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Hansa Biopharma AB’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Clinical Trials

Determine Hansa Biopharma AB go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

6

Pipeline Drugs

Identify which of Hansa Biopharma AB’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Hansa Biopharma AB’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products Brands
Pipeline Drugs: Idefirix
Imlifidase:
Kidney Transplantation
XYZ
XYZ
XYZ
Understand Hansa Biopharma AB portfolio and identify potential areas for collaboration Understand Hansa Biopharma AB portfolio and identify potential areas for collaboration Learn more
Image for loader

Competitor Comparison

Key Parameters Hansa Biopharma AB Swedish Orphan Biovitrum AB Calliditas Therapeutics AB BioInvent International AB Diamyd Medical AB
Headquarters Sweden Sweden Sweden Sweden Sweden
City Lund Stockholm Stockholm Lund Stockholm
State/Province - Stockholm Stockholm - -
No. of Employees 122 1,969 192 112 41
Entity Type Public Public Private Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Peter Nicklin Chairman Executive Board 2022 63
Renee Aguiar-Lucander Chief Executive Officer Senior Management 2025 -
Adam Cutler Chief Financial Officer Senior Management 2026 -
Maria Tornsen President - US; Chief Operating Officer Senior Management 2025 -
Hitto Kaufmann, Ph.D Chief Scientific Officer; Chief Technology Officer Senior Management 2023 56
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Hansa Biopharma AB key executives to enhance your sales strategy Gain insight into Hansa Biopharma AB key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?